ATP binding site inhibitors are small molecules designed to bind to the ATP binding site of target proteins, thereby blocking ATP from binding. This inhibition can deactivate the protein and halt the downstream signaling pathways that promote cancer cell growth and survival. Examples of such inhibitors include tyrosine kinase inhibitors (TKIs) like imatinib, which targets the ATP binding site of the BCR-ABL protein in chronic myeloid leukemia.
